Auditor Resigns at RetinalGenix Amid Liquidity Crunch — Successor Named
RTGN has more than doubled off its 52-week low of $0.25.
Summary
RetinalGenix's auditor resigned effective July 13, 2026, and the company appointed Vilki & Co. as its new auditor on July 15. The change comes as the company faces a severe cash shortage, with only $180 on hand at the end of Q1 2026.
Key Events · Legal and Risk Events · RTGN
-
Auditor Resignation
Liebman Hymowitz, LLP resigned as RetinalGenix's independent auditor on July 13, 2026. The firm's audit reports for 2024 and 2025 included a going-concern explanatory paragraph.
-
New Auditor Appointed
Vilki & Co., Charted Accountants, was engaged as the new independent auditor on July 15, 2026, effective immediately. No prior consultations occurred between the company and Vilki & Co. on accounting matters.
-
No Disagreements Reported
The company stated there were no disagreements with the former auditor on accounting principles or practices, and no reportable events beyond previously disclosed internal control matters.
-
Liquidity Crisis Backdrop
The auditor change occurs as RetinalGenix faces an extreme liquidity crisis, with only $180 in cash as of March 31, 2026, and a recent $200,000 capital raise providing limited runway.
Analysis · RTGN · Industrial Applications And Services
On July 13, 2026, RetinalGenix's auditor, Liebman Hymowitz, resigned, and the company promptly engaged Vilki & Co. as its new auditor. The outgoing firm's reports for 2024 and 2025 carried a going-concern warning, and as of March 31, 2026, the company held just $180 in cash. An auditor change during a liquidity crisis raises concerns about financial reporting continuity and potential undisclosed issues, though no disagreements were reported. The swift appointment of a new firm provides some stability, but the timing and circumstances warrant close attention.
At the time of this filing, RTGN was trading at $4.00 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $75M. The 52-week trading range was $0.25 to $20.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.